Clinical Trial Update: Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety of two doses of EVP-6124 in people with Alzheimer's disease who are receiving memantine has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Alzheimer's Disease, Dementia | Phase 2 | Status: WITHDRAWN